Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Author:

Garcia-Manero Guillermo1,Yang Hui1,Bueso-Ramos Carlos1,Ferrajoli Alessandra1,Cortes Jorge1,Wierda William G.1,Faderl Stefan1,Koller Charles1,Morris Gail1,Rosner Gary1,Loboda Andrey2,Fantin Valeria R.2,Randolph Sophia S.2,Hardwick James S.2,Reilly John F.2,Chen Cong2,Ricker Justin L.2,Secrist J. Paul2,Richon Victoria M.2,Frankel Stanley R.2,Kantarjian Hagop M.1

Affiliation:

1. Departments of Leukemia, Hematopathology, and Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston and

2. Merck, Whitehouse Station, NJ

Abstract

AbstractVorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest. Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible. Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia. The maximum tolerated dose (MTD) was 200 mg twice daily or 250 mg thrice daily. Dose-limiting toxicities were fatigue, nausea, vomiting, and diarrhea. Common drug-related adverse experiences were diarrhea, nausea, fatigue, and anorexia and were mild/moderate in severity. Grade 3/4 drug–related adverse experiences included fatigue (27%), thrombocytopenia (12%), and diarrhea (10%). There were no drug-related deaths; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD). Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference48 articles.

1. Histone deacetylases and cancer: causes and therapies.;Marks;Nat Rev Cancer,2001

2. Histone acetylation and disease.;Timmermann;Cell Mol Life Sci,2001

3. Histone deacetylase inhibitors: understanding a new wave of anticancer agents.;Villar-Garea;Int J Cancer,2004

4. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.;Glick;Cancer Res,1999

5. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.;Peart;Proc Natl Acad Sci U S A,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3